Literature DB >> 22808522

NMDA receptors in the medial prefrontal cortex and the dorsal hippocampus regulate methamphetamine-induced hyperactivity and extracellular amino acid release in mice.

Wenyan Han1, Fangyang Wang, Jia Qi, Fang Wang, Lijia Zhang, Siqi Zhao, Ming Song, Chunfu Wu, Jingyu Yang.   

Abstract

The medial prefrontal cortex (mPFC) and the dorsal hippocampus (DHC) play significant roles in stimulant-induced neurobehavioral effects. Methamphetamine (MAP)-induced hyperactivity has been reported to be involved in the regulation of the glutamatergic system. The present study examined whether the glutamatergic and GABAergic systems in the mPFC and DHC were involved in MAP-induced hyperactivity in mice. A combined kainic acid (KA) or N-methyl-d-aspartate (NMDA) lesion and microdialysis technique targeting both the mPFC and DHC were used. The results showed that both KA- and NMDA-induced lesions of the mPFC facilitated MAP-induced hyperactivity, while neither KA- nor NMDA-induced lesions of the DHC had a similar effect. MAP increased the extracellular glutamate (Glu) levels in the mPFC and reduced Glu levels in the DHC. GABA levels in both of these regions were reduced. A KA or NMDA lesion of the mPFC inhibited the Glu reduction in the DHC, and the same lesion of the DHC inhibited the Glu increase in the mPFC induced by MAP. A NMDA lesion of the mPFC blocked GABA reduction in the DHC, but a lesion of DHC enhanced the GABA decrease in the mPFC induced by MAP. Furthermore, a NMDA lesion of DHC increased the vesicular glutamate transporter-2 (VGLUT2) expression in the mPFC following MAP-administration. These findings indicate that glutamatergic as well as GABAergic systems in these two regions are involved in MAP-induced hyperactivity. Moreover, there may be an inhibitory role in these two regions, especially mediated by NMDA receptors, in MAP-induced abnormal behavior and neurotransmission responses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22808522     DOI: 10.1016/j.bbr.2012.03.038

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  5 in total

1.  Insular neural system controls decision-making in healthy and methamphetamine-treated rats.

Authors:  Hiroyuki Mizoguchi; Kentaro Katahira; Ayumu Inutsuka; Kazuya Fukumoto; Akihiro Nakamura; Tian Wang; Taku Nagai; Jun Sato; Makoto Sawada; Hideki Ohira; Akihiro Yamanaka; Kiyofumi Yamada
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-06       Impact factor: 11.205

2.  Neuroadaptations in the dentate gyrus following contextual cued reinstatement of methamphetamine seeking.

Authors:  Yoshio Takashima; McKenzie J Fannon; Melissa H Galinato; Noah L Steiner; Michelle An; Alice E Zemljic-Harpf; Sucharita S Somkuwar; Brian P Head; Chitra D Mandyam
Journal:  Brain Struct Funct       Date:  2018-02-13       Impact factor: 3.270

3.  Low-normal doses of methiopropamine induce aggressive behaviour in mice.

Authors:  Federica Foti; Sabrine Bilel; Fabio De-Giorgio; Matteo Marti; Micaela Tirri; Raffaella Arfè; Federica Boccuto; Tatiana Bernardi; Giovanni Serpelloni
Journal:  Psychopharmacology (Berl)       Date:  2021-03-26       Impact factor: 4.530

4.  Prefrontal glutamate correlates of methamphetamine sensitization and preference.

Authors:  Kevin D Lominac; Sema G Quadir; Hannah M Barrett; Courtney L McKenna; Lisa M Schwartz; Paige N Ruiz; Melissa G Wroten; Rianne R Campbell; Bailey W Miller; John J Holloway; Katherine O Travis; Ganesh Rajasekar; Dan Maliniak; Andrew B Thompson; Lawrence E Urman; Tod E Kippin; Tamara J Phillips; Karen K Szumlinski
Journal:  Eur J Neurosci       Date:  2016-02-22       Impact factor: 3.386

5.  Effects of the GluN2B-selective antagonist Ro 63-1908 on acquisition and expression of methamphetamine conditioned place preference in male and female rats.

Authors:  Justin R Yates; Hunter L Campbell; Lauren L Hawley; Matthew J Horchar; Joy L Kappesser; Makayla R Wright
Journal:  Drug Alcohol Depend       Date:  2021-05-26       Impact factor: 4.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.